Insulet | PODD - Cash And Equivalent



Insulet reported $1.12B in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
Abbott USD 6.95B 419M Jun/2025
Align Technology USD 873.01M 170.88M Mar/2025
AtriCure USD 117.8M 17.91M Jun/2025
Avanos Medical USD 90.3M 6.7M Jun/2025
Baxter International USD 2.29B 530M Mar/2025
Becton, Dickinson and Co. USD 735M 68M Jun/2025
Boston Scientific USD 725M 311M Mar/2025
Cardinal Health USD 3.87B 548M Jun/2025
Cooper Companies USD 124.9M 8.7M Jul/2025
Dexcom USD 1.16B 254.1M Jun/2025
Edwards Lifesciences USD 3.14B 95.4M Mar/2025
Eli Lilly USD 3.38B 282.6M Jun/2025
Globus Medical USD 229.45M 231.82M Jun/2025
ICU Medical USD 300.02M 10.32M Jun/2025
Insulet USD 1.12B 107M Jun/2025
Integra LifeSciences USD 217.91M 21.19M Jun/2025
J&J USD 38.47B 32.35B Mar/2025
Masimo USD 149.6M 18.8M Jun/2025
Medtronic USD 2.22B 978M Apr/2025
Merit Medical Systems USD 341.82M 53.71M Jun/2025
Roche Holding CHF 6.98B 2.15B Dec/2024
Solventum Corp 492M 42M Jun/2025
Stryker USD 2.38B 55M Jun/2025
Tandem Diabetes Care USD 64.11M 10.54M Jun/2025
Teleflex USD 253.7M 30.42M Jun/2025
West Pharmaceutical Services USD 509.7M 105.5M Jun/2025
Zimmer Biomet Holdings USD 556.9M 827.6M Jun/2025